Cargando…

Effect of 5-HT(6) Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats

BACKGROUND: The presence of depressive and anxiety symptoms in patients with schizophrenia may have an important impact on treatment and compliance. Hence, interventions addressing such comorbidity in schizophrenia should be explored. One target may be a serotonergic 5-HT(6) receptor (5-HT(6)R) sinc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wesołowska, Anna, Rychtyk, Joanna, Gdula-Argasińska, Joanna, Górecka, Katarzyna, Wilczyńska-Zawal, Natalia, Jastrzębska-Więsek, Magdalena, Partyka, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240864/
https://www.ncbi.nlm.nih.gov/pubmed/34211274
http://dx.doi.org/10.2147/NDT.S309818
_version_ 1783715288965971968
author Wesołowska, Anna
Rychtyk, Joanna
Gdula-Argasińska, Joanna
Górecka, Katarzyna
Wilczyńska-Zawal, Natalia
Jastrzębska-Więsek, Magdalena
Partyka, Anna
author_facet Wesołowska, Anna
Rychtyk, Joanna
Gdula-Argasińska, Joanna
Górecka, Katarzyna
Wilczyńska-Zawal, Natalia
Jastrzębska-Więsek, Magdalena
Partyka, Anna
author_sort Wesołowska, Anna
collection PubMed
description BACKGROUND: The presence of depressive and anxiety symptoms in patients with schizophrenia may have an important impact on treatment and compliance. Hence, interventions addressing such comorbidity in schizophrenia should be explored. One target may be a serotonergic 5-HT(6) receptor (5-HT(6)R) since its ligands displayed antidepressant- and anxiolytic-like activities in preclinical experiments. METHODS: Acute and chronic (21 days) administration of haloperidol or risperidone in combination with a selective 5-HT(6)R agonist (WAY-181187) or antagonist (SB-742457) to rats was performed for detecting antidepressant- and anxiolytic-like behaviors. In addition, the level of brain-derived neurotrophic factor (BDNF) protein and its gene expression in hippocampus and prefrontal cortex were determined. RESULTS: Both single and chronic administration of WAY-181187 with haloperidol produced antidepressant- and anxiolytic-like activities. SB-742457 did not provide full benefits in terms of improvement of haloperidol-induced adverse mood effects. However, the administration of SB-742457 with risperidone triggered its anxiolytic-like activity. Both 5-HT(6)R ligands evoked no changes in haloperidol-induced effects on BDNF level. WAY-181187 induced repression of the BDNF gene while SB-742457 increased its expression in both structures. 5-HT(6)R ligands, when combined with risperidone, did not change BDNF protein level and increased gene expression in the hippocampus, while they elevated BDNF level and potentiated gene expression in the prefrontal cortex. CONCLUSION: The combined administration of WAY-181187 and haloperidol provided the greatest benefits, which were manifested by antidepressant-like effects and suppression of the anxiogenic-like properties. The combined administration of risperidone with both agonist and antagonist resulted only in an anxiolytic-like effect. It seems that the anxiolytic-like effects induced by haloperidol or risperidone with the addition of 5-HT(6)R ligands are task-specific. The data on BDNF protein and gene expression did not fully correspond with the behavioral outcomes, and thus it appears that other factors/mechanisms are involved in the observed antidepressant- and/or anxiolytic-like effects.
format Online
Article
Text
id pubmed-8240864
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82408642021-06-30 Effect of 5-HT(6) Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats Wesołowska, Anna Rychtyk, Joanna Gdula-Argasińska, Joanna Górecka, Katarzyna Wilczyńska-Zawal, Natalia Jastrzębska-Więsek, Magdalena Partyka, Anna Neuropsychiatr Dis Treat Original Research BACKGROUND: The presence of depressive and anxiety symptoms in patients with schizophrenia may have an important impact on treatment and compliance. Hence, interventions addressing such comorbidity in schizophrenia should be explored. One target may be a serotonergic 5-HT(6) receptor (5-HT(6)R) since its ligands displayed antidepressant- and anxiolytic-like activities in preclinical experiments. METHODS: Acute and chronic (21 days) administration of haloperidol or risperidone in combination with a selective 5-HT(6)R agonist (WAY-181187) or antagonist (SB-742457) to rats was performed for detecting antidepressant- and anxiolytic-like behaviors. In addition, the level of brain-derived neurotrophic factor (BDNF) protein and its gene expression in hippocampus and prefrontal cortex were determined. RESULTS: Both single and chronic administration of WAY-181187 with haloperidol produced antidepressant- and anxiolytic-like activities. SB-742457 did not provide full benefits in terms of improvement of haloperidol-induced adverse mood effects. However, the administration of SB-742457 with risperidone triggered its anxiolytic-like activity. Both 5-HT(6)R ligands evoked no changes in haloperidol-induced effects on BDNF level. WAY-181187 induced repression of the BDNF gene while SB-742457 increased its expression in both structures. 5-HT(6)R ligands, when combined with risperidone, did not change BDNF protein level and increased gene expression in the hippocampus, while they elevated BDNF level and potentiated gene expression in the prefrontal cortex. CONCLUSION: The combined administration of WAY-181187 and haloperidol provided the greatest benefits, which were manifested by antidepressant-like effects and suppression of the anxiogenic-like properties. The combined administration of risperidone with both agonist and antagonist resulted only in an anxiolytic-like effect. It seems that the anxiolytic-like effects induced by haloperidol or risperidone with the addition of 5-HT(6)R ligands are task-specific. The data on BDNF protein and gene expression did not fully correspond with the behavioral outcomes, and thus it appears that other factors/mechanisms are involved in the observed antidepressant- and/or anxiolytic-like effects. Dove 2021-06-25 /pmc/articles/PMC8240864/ /pubmed/34211274 http://dx.doi.org/10.2147/NDT.S309818 Text en © 2021 Wesołowska et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wesołowska, Anna
Rychtyk, Joanna
Gdula-Argasińska, Joanna
Górecka, Katarzyna
Wilczyńska-Zawal, Natalia
Jastrzębska-Więsek, Magdalena
Partyka, Anna
Effect of 5-HT(6) Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats
title Effect of 5-HT(6) Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats
title_full Effect of 5-HT(6) Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats
title_fullStr Effect of 5-HT(6) Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats
title_full_unstemmed Effect of 5-HT(6) Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats
title_short Effect of 5-HT(6) Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats
title_sort effect of 5-ht(6) receptor ligands combined with haloperidol or risperidone on antidepressant-/anxiolytic-like behavior and bdnf regulation in hippocampus and prefrontal cortex of rats
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240864/
https://www.ncbi.nlm.nih.gov/pubmed/34211274
http://dx.doi.org/10.2147/NDT.S309818
work_keys_str_mv AT wesołowskaanna effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats
AT rychtykjoanna effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats
AT gdulaargasinskajoanna effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats
AT goreckakatarzyna effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats
AT wilczynskazawalnatalia effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats
AT jastrzebskawiesekmagdalena effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats
AT partykaanna effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats